about
Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia.Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndromeGenomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2.Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signalingHigh expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndromeGenetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma.Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes.Downregulation of p21 in myelodysplastic syndrome is associated with p73 promoter hypermethylation and indicates poor prognosis.Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway.Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells.Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine
P50
Q33426885-9ACE0203-CB58-4B44-BDC3-4DAD5F52E310Q33725731-3DD89841-0C1C-4644-A041-CA1DA33C8FA1Q33767762-CAAF3AEE-E737-441C-8B7A-06C57417847FQ36309518-5D6BA2AA-A384-42DE-B79E-0BCDA12989D6Q36360964-26B5F5F8-BFDE-4AC6-9DDD-9C553D176AA8Q36654373-04C4607A-D0CC-46AB-8016-383FFA9CEEE7Q37144116-DE1807EB-1934-4C67-84F0-7F6F142315CAQ37666492-7259E8E1-B8EF-4C9F-A1AE-151FFA00C90CQ40385815-1E7168D6-FE17-4B6E-9E55-4537301DD255Q40421122-5E6EA17D-73BA-4E98-8281-88AD915F25A9Q40857619-26552C72-D0FF-42E4-9B4B-6B58138BE51BQ41331089-464B7532-A953-4E89-89CC-ACECD039A140Q41548439-E8D8F5BF-0CE4-40F4-A3BD-6D04C3EC1E2AQ49114034-CF4F65C2-98DC-4494-BDBE-C111834AB18FQ50480672-F4946F9B-EC4C-4819-BEE9-2F595FEC24BEQ51790001-93A76C01-68C2-4495-B57B-8F0BAEBFB40EQ53083193-C0876D4C-A393-4BE4-BF4A-E399D8BF32F5Q53122486-F44BD72B-521B-4E7A-B221-9069635B71B3Q54348216-D2D1B8D6-EC49-40F5-A334-D90F906A39D6Q54979795-F7571165-1CFF-4183-B691-7E2CC3ECBE9CQ54982598-0B5A048A-FBCA-4AA2-A3EB-1B2D142D61ECQ86423072-3F31F74B-31B1-43B0-88B5-B0834247F496
P50
description
investigador
@es
researcher
@en
name
Chunkang Chang
@en
type
label
Chunkang Chang
@en
prefLabel
Chunkang Chang
@en
P31
P496
0000-0001-5318-5879